WallStSmart

Abbott Laboratories (ABT)vsWPP PLC ADR (WPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 233% more annual revenue ($45.13B vs $13.55B). ABT leads profitability with a 13.9% profit margin vs -1.6%. ABT appears more attractively valued with a PEG of 1.29. ABT earns a higher WallStSmart Score of 56/100 (C).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 6.0Quality: 4.8
Piotroski: 3/9

WPP

Avoid

32

out of 100

Grade: F

Growth: 2.0Profit: 3.0Value: 5.7Quality: 2.5
Piotroski: 3/9Altman Z: 0.73
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTUndervalued (+0.6%)

Margin of Safety

+0.6%

Fair Value

$87.53

Current Price

$84.32

$3.21 discount

UndervaluedFair: $87.53Overvalued
WPPUndervalued (+75.6%)

Margin of Safety

+75.6%

Fair Value

$75.12

Current Price

$18.97

$56.15 discount

UndervaluedFair: $75.12Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$151.56B9/10

Large-cap with strong market position

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

WPP1 strengths · Avg: 8.0/10
Free Cash FlowQuality
$1.71B8/10

Generating 1.7B in free cash flow

Areas to Watch

ABT2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

WPP4 concerns · Avg: 2.5/10
Operating MarginProfitability
2.2%3/10

Operating margin of 2.2%

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.232/10

Expensive relative to growth rate

Return on EquityProfitability
-5.3%2/10

ROE of -5.3% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Price/Book. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bull Case : WPP

The strongest argument for WPP centers on Free Cash Flow.

Bear Case : ABT

The primary concerns for ABT are Piotroski F-Score, EPS Growth.

Bear Case : WPP

The primary concerns for WPP are Operating Margin, Piotroski F-Score, PEG Ratio. Debt-to-equity of 2.13 is elevated, increasing financial risk.

Key Dynamics to Monitor

ABT profiles as a value stock while WPP is a turnaround play — different risk/reward profiles.

WPP carries more volatility with a beta of 0.65 — expect wider price swings.

ABT is growing revenue faster at 7.8% — sustainability is the question.

WPP generates stronger free cash flow (1.7B), providing more financial flexibility.

Bottom Line

ABT scores higher overall (56/100 vs 32/100). WPP offers better value entry with a 75.6% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

WPP PLC ADR

COMMUNICATION SERVICES · ADVERTISING AGENCIES · USA

WPP plc, a creative transformation company, provides communications, expertise, trade and technology services in North America, the UK, Western Continental Europe, Asia Pacific, Latin America, Africa, the Middle East, and Central and Eastern Europe. The company is headquartered in London, the United Kingdom.

Visit Website →

Want to dig deeper into these stocks?